Basit öğe kaydını göster

dc.contributor.authorSolmaz, Soner
dc.contributor.authorKaracaoglu, Pelin
dc.contributor.authorGereklioglu, Cigdem
dc.contributor.authorAsma, Suheyl
dc.contributor.authorKorur, Asli
dc.contributor.authorBuyukkurt, Nurhilal
dc.contributor.authorKasar, Mutlu
dc.contributor.authorYeral, Mahmut
dc.contributor.authorKozanoglu, Ilknur
dc.contributor.authorBoga, Can
dc.contributor.authorOzdogu, Hakan
dc.date.accessioned2019-06-17T08:23:13Z
dc.date.available2019-06-17T08:23:13Z
dc.date.issued2016
dc.identifier.issn0250-5150
dc.identifier.urihttps://dergipark.org.tr/download/article-file/221291
dc.identifier.urihttp://hdl.handle.net/11727/3572
dc.description.abstractPurpose: We aimed to investigate erythrocyte alloimmunization frequency and related factors in our region where SCD is common Material and Methods: This study was planned as a single center, cross-sectional and retrospective cohort study. A total of 216 patients who had been followed up due to SCD [Hemoglobin (Hb) SS, Hb S-beta thalassemia, Hb S-alpha thalassemia] were included in this study. Patients were divided to two groups according to amount of transfusion. The patients who had received less than 6 transfusions per year and who did not have the history of erythropheresis were allocated to Group 1, and the patients who had received 6 or more simple transfusion per year or who had undergone erythrocyte exchange were allocated to Group 2 Results: Of 216 SCD patients included in the study. Alloimmunization was detected in 67 (31.0%) out of 216 patients who underwent transfusion, and in 17 (30.4%) out of 56 patients in Group 1 and in 50 (31.3%) out of 160 patients in Group 2. When the patients were analyzed according to alloimmunization development, our study revealed that neither SCD complications are a risk factor for alloimmunization nor alloimmunization increases mortality rates Conclusion: High alloimmunization frequency found in our study suggests the insufficient adherence of alloimmunization-prevention policies in RBC transfusions performed except experienced institutions. Therefore alloimmunization may be reduced or prevented through performing extended red cell typing among SCD patientsen_US
dc.language.isoturen_US
dc.relation.isversionof10.17826/cutf.254171en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSickle cell diseaseen_US
dc.subjectTransfusionen_US
dc.subjectAlloimmunizationen_US
dc.titleRed blood cell alloimmunization in patients with sickle cell disease in Turkey: a single center retrospective cohort studyen_US
dc.typearticleen_US
dc.relation.journalCUKUROVA MEDICAL JOURNALen_US
dc.identifier.volume41en_US
dc.identifier.issue4en_US
dc.identifier.startpage622en_US
dc.identifier.endpage627en_US
dc.identifier.wos000399391600002en_US
dc.contributor.orcID0000-0002-5086-5593en_US
dc.contributor.orcID0000-0002-8902-1283en_US
dc.contributor.orcID0000-0003-3856-7005en_US
dc.contributor.orcID0000-0002-0895-4787en_US
dc.contributor.orcID0000-0002-5268-1210en_US
dc.contributor.orcID0000-0002-9680-1958en_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergien_US
dc.contributor.researcherIDAAD-5616-2021en_US
dc.contributor.researcherIDAAD-5542-2021en_US
dc.contributor.researcherIDAAL-3906-2021en_US
dc.contributor.researcherIDAAE-1457-2021en_US
dc.contributor.researcherIDABC-4148-2020en_US
dc.contributor.researcherIDAAD-6222-2021en_US
dc.contributor.researcherIDAAE-1241-2021en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster